No abstract available.
Risperidone*

21 patients with chronic schizopherenia (male: 15) with ages of 17-58 treated by Risperdal at dose of 3.96 mg/day within 8 weeks has shown that scores of PANSS scale, possitive scale and general scale were statistical significantly reduced (P< 0.001), score of negative scale was statistical significantly reduced (P < 0.001). The drug had a good tolerability (83.9% patients). The side-effects and complications including extrapyramidal syndrome were mild and not frequent. The efficacy was 80.6%.
Risperidone ; Schizophrenia

No abstract available.
Mood Disorders* ; Risperidone*

There are several case reports on risperidone-related bleeding; however, to our knowledge, there is no report about gingival bleeding associated with risperidone in the literature. We presented a case who experienced gingival bleeding when risperidone dose was increased to 0.5 mg/day, and subsided after decreasing the dose to 0.25 mg/day, suggesting a dose-dependent side-effect. The bleeding side effect of risperidone might be caused by several mechanisms, including 5-hydroxytryptamine 2A receptor antagonism. Although bleeding associated with risperidone is rarely reported, clinicians should be aware of this side effect.
Child ; Hemorrhage* ; Humans ; Risperidone ; Serotonin

It has been reported that risperidone, an atypical antipsychotic drug, is less likely to induce neurologic side effects than conventional antipsychotics. However, long-term administration of risperidone has been reported to produce severe irreversible neurologic side effects, such as tardive dyskinesia. Tardive dystonia has been suggested as a distinct movement disorder different from tardive dyskinesia and a few cases of risperidone-induced tardive dystonia were reported recently. We experienced two cases of tardive dystonia, which developed in association with the long-term administration of risperidone, and the symptoms of tardive dystonia were slightly subsided after discontinuation of risperidone. It is necessary to be cautious of dystonic symptoms during long-term administration of risperidone.
Antipsychotic Agents ; Movement Disorders* ; Risperidone

BACKGROUNDS: Behavioral and psychological symptoms as well as cognitive impairement are very disturbing symptoms in dementia. It is important in managing dementia patient to control these behavioral and psychological symptoms. In this study, we examined the effect of risperidone and optimal therapeutic dosage on controlling these behavioral and psychological symptoms of dementia (BPSD). METHODS: 57 patients (male: 19, female: 38) with dementia, aged 65 and older in Buyeo geriatric hospital located in Buyeo-gun, chung-nam, were finally included in this study. risperidone was administrated to these subjects for 10 weeks to control BPSD. Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD) was rated before administration of risperidone and after administration of risperidone for 10 weeks to evaluate the improvement of BPSD. Global Deterioration Scale (GDS) was rated before administration of risperidone. The correlation between baseline GDS score and the change of sum score of BEHAVE-AD was analyzed. RESULT: The mean dose of resperidone at the endpoint was 0.706+/-0.522 mg/d. The significant reduction of the sum score of BEHAVE-AD was observed in subjects after administration of risperidone for 10 weeks. Clinical improvement (> or =50% reduction of sum score of BEHAVE-AD from baseline sum score) was showed in 32 subjects (56.1%) among 57 subjects. Also there was weakly negative correlation between baseline GDS score and the change of sum score of BEHAVE0AD. CONCLUSION: Risperidone was effective in controlling BPSD of dementia patients at 0.706+/-0.522 mg/d.
Alzheimer Disease ; Dementia* ; Female ; Humans ; Pathology ; Risperidone*

The Pisa syndrome is a rare extrapyramidal side effect caused by neuroleptic treatment. Its characteristics are the twist-ing and bending to one side of the upper thorax, the neck, and the head. To our knowledge, there have been no reports of Pisa syndrome in risperidone therapy. We report four male patients with Pisa syndrome in risperidone therapy. Significant points to be noted here are the absence of any extrapyramidal symptoms prior to risperidone therapy, occur-rence in risperidone therapy with small dosages, and delayed spontaneous recovery on discontinuation of risperidone.
Head ; Humans ; Male ; Neck ; Risperidone* ; Thorax

A few cases describing hepatotoxicity associated with administration of risperidone have been repo-rted. In most cases, the abnormal liver function was normalized without specific treatment. Therefore, it has not been strictly recommended for monitoring liver function during a treatment with risperidone. We experienced a case of risperidone-induced hepatotoxicity which was not normalized spontaneously in a patient with schizophrenia. The liver enzyme was elevated according to the administration of risperidone continuously, and normalized only after discontinuation of risperidone. Unlike previous reports, the patient had no history of liver disease and demonstrated abnormal liver function from the relatively earlier period of treatment. Therefore, we recommend that it is necessary to be cautious of monitoring liver function during administration of risperidone.
Humans ; Liver ; Liver Diseases ; Risperidone ; Schizophrenia

There have been 91 papers on risperidone in Korea, which were composed of 21 reviews, 9 preclinical studies, 18 case reports, and 43 clinical trials, since this new antipsychotic was introduced. Case reports focused mainly on adverse effects of risperidone, and clinical trials on it's efficacy and safety. Review of Korean clinical trials revealed the paucity of well designed controlled studies which examined the effective dose and compared the efficacy of risperidone with those of other drugs. Future research should adopt more reliable and standardized methods. The efficacy of risperidone for various clinical populations needs to be elucidated. Researchers need to make an effort to implicate the clinical use of risperidone. Long-term outcome studies are expected.
Korea* ; Outcome Assessment (Health Care) ; Risperidone*

OBJECTIVES: The aim of this study is to evaluate the effect of risperidone on attention and information-processing in schizophrenic patients after 8 weeks of treatment and to determine whether any improvement on cognitive function relates to improvement in psychopathology. METHODS: The subjects were 29 schizophrenic inpatients with active psychotic symptoms and the controls were 25 normal volunteers. Pre- and post-treatment clinical symptoms were assessed by Positive and Negative Syndrome Scale, Clinical Global Impression and Extrapyramidal Symptom Rating Scale. Vigilance, continuous atttention, the speed of information-processing and fine motor coordinations were assessed by standardized computerized neurocognitive function tests. RESULTS: At baseline, patients showed significantly poor vigilance and continuous attention than normal controls and these functions were not improved after treatment. The positive and negative symptoms and the general psychopathology were significantly improved. The only item of cognitive tasks signi-fica-ntly improved after treatment was decision time to complex audio-visual stimuli in information-processing task. This improvement was not related to the improvements in psychopathology. The level of extrapyramidal symptoms was not related with any of the cognitive fucntion tests items. CONCLUSIONS: Treatment with risperidone appeared to exert a favorable effect on the speed of information-processing and this appeared to be due to a direct pharmacodynamic characteristics of the drug.
Healthy Volunteers ; Humans ; Inpatients ; Psychopathology ; Risperidone* ; Schizophrenia*